Latest News - Clearside Biomedical

Monday, November 13, 2017 | Clinical Trials, Clearside Biomedical

Clearside Biomedical’s Phase 1/2 Open-Label Clinical Trial of CLS-TA With and Without Eylea in DME Presented at AAO

Charles C. Wykoff, MD, PhD, presented preliminary results from an exploratory clinical trial (the HULK trial) of CLS-TA, Clearside’s proprietary suspension formulation of the corticosteroid tria…

Read the full story

Wednesday, October 25, 2017 | Clinical Trials, Retina, Clearside Biomedical

Clearside Biomedical Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CLS-TA Used Together with Eylea in Patients with DME

Clearside Biomedical announced completion of patient enrollment in the phase 2 clinical trial (TYBEE) of CLS-TA, Clearside’s proprietary suspension formulation of the corticosteroid triamcinolon…

Read the full story

Tuesday, August 01, 2017 | Clinical Trials, Retina, Clearside Biomedical

First Patient Randomized in Clearside's Phase 2 Trial of CLS-TA with Eylea for DME

Clearside Biomedical announced enrollment of the first patient in a phase 2 clinical trial (TYBEE) of CLS-TA for suprachoroidal administration, Clearside’s proprietary suspension formulation of …

Read the full story

Thursday, April 20, 2017 | Clinical Trials, Clearside Biomedical

Clearside Biomedical Announces Completion of Patient Enrollment in Phase 1/2 Clinical Trial of CLS-TA in Diabetic Macular Edema

Clearside Biomedical announced completion of enrollment of an exploratory clinical trial (HULK trial) of CLS-TA for suprachoroidal administration, its proprietary suspension formulation of the cortico…

Read the full story

Friday, March 31, 2017 | Partnerships, Clearside Biomedical

Clearside Biomedical Enters into Strategic Collaboration with EyeKor to Support Clinical Development Efforts

Clearside Biomedical announced that it has entered into a strategic collaboration with EyeKor to support Clearside’s ophthalmic clinical trial activities. Clearside is currently conducting ph…

Read the full story

Thursday, February 16, 2017 | Clinical Trials, Clearside Biomedical

Clearside Biomedical Announces First Patient Randomized in Phase 3 Clinical Trial of Zuprata Used Together With Eylea in Subjects With RVO

Clearside Biomedical announced the enrollment of the first patient in a phase 3 clinical trial (SAPPHIRE) of Zuprata, its proprietary suspension formulation of the corticosteroid triamcinolone acetoni…

Read the full story

Monday, October 10, 2016 | Clinical Trials, Clearside Biomedical

Clearside Biomedical to Report Clinical Trial Results at 2016 Retina Subspecialty Day Meeting at the American Academy of Ophthalmology Meeting

Clearside Biomedical announced that results from two clinical trials, including the TANZANITE trial, “Safety and Efficacy of Suprachoroidal Triamcinolone Acetonide Concomitant with Intravitreal …

Read the full story

Tuesday, July 26, 2016 | Clinical Trials, Clearside Biomedical

Clearside Biomedical Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with RVO

Clearside Biomedical reported additional topline data from its phase 2 clinical trial (TANZANITE). The 46-patient trial, with topline results originally reported in April 2016, evaluated the treatment…

Read the full story

Thursday, June 02, 2016 | Earnings & Financials, Clearside Biomedical

Clearside Biomedical Announces Pricing of Initial Public Offering

Clearside Biomedical announced the pricing of its initial public offering of 7,200,000 shares of its common stock at a public offering price of $7.00 per share, according to a company news relea…

Read the full story

Thursday, April 28, 2016 | Conferences, Clearside Biomedical

Clearside Biomedical to Present Data on Suprachoroidal Drug Administration at 2016 ARVO Meeting

Clearside Biomedical announced four poster presentations associated with suprachoroidal drug administration will be presented at the 2016 Annual Meeting of the Association for Research in Vision and O…

Read the full story

Tuesday, April 26, 2016 | Clinical Trials, Clearside Biomedical

Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients with Macular Edema Associated with RVO

Clearside Biomedical announced that its phase 2 clinical trial evaluating concomitant administration of suprachoroidal Zuprata, Clearside’s proprietary form of triamcinolone acetonide, together …

Read the full story

Tuesday, January 05, 2016 | Clinical Trials, Clearside Biomedical

Clearside Biomedical Announces Positive Topline Data from Phase 2 Clinical Trial for the Treatment of Macular Edema Associated with Non-Infectious Uveitis

Clearside Biomedical announced positive results from the company’s phase 2 clinical trial of CLS-TA, Clearside’s proprietary form of triamcinolone acetonide, using suprachoroidal space (SC…

Read the full story

Monday, December 14, 2015 | Clinical Trials, Clearside Biomedical

Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space (SCS) Drug Administration

Clearside Biomedical announced completion of enrollment in the company’s phase 2 clinical trial (Tanzanite) for the treatment of macular edema associated with retinal vein occlusion (RVO), accor…

Read the full story

Monday, December 07, 2015 | Clinical Trials, Clearside Biomedical

Clearside Biomedical Enrolls First Patient in Phase 3 Clinical Trial of CLS-TA Using Suprachoroidal Drug Administration

Clearside Biomedical announced that the first patient was enrolled in Clearside’s phase 3 clinical trial, Peachtree, of CLS-TA, Clearside’s proprietary form of triamcinolone acetonid…

Read the full story

Monday, October 12, 2015 | Clinical Trials, Clearside Biomedical

Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA Using Suprachoroidal Space

Clearside Biomedical announced completion of enrollment in the company’s phase 2 clinical trial (Dogwood) of CLS-TA, Clearside’s proprietary form of triamcinolone acetonide, using su…

Read the full story
Load More